CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Update

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) was the recipient of a large growth in short interest in August. As of August 31st, there was short interest totalling 9,400 shares, a growth of 11.9% from the August 15th total of 8,400 shares. Based on an average daily volume of 12,800 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.1% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on CLGN shares. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of CollPlant Biotechnologies in a research report on Wednesday, August 21st. EF Hutton Acquisition Co. I raised shares of CollPlant Biotechnologies to a “strong-buy” rating in a research note on Monday, August 5th.

CollPlant Biotechnologies Trading Down 0.2 %

CLGN stock traded down $0.01 during mid-day trading on Monday, hitting $5.00. The stock had a trading volume of 2,078 shares, compared to its average volume of 9,516. CollPlant Biotechnologies has a 1-year low of $4.10 and a 1-year high of $6.99. The company has a fifty day moving average of $4.91 and a 200 day moving average of $5.24. The stock has a market capitalization of $57.27 million, a price-to-earnings ratio of -7.35 and a beta of 0.31.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its quarterly earnings results on Tuesday, August 20th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.70 million. CollPlant Biotechnologies had a negative net margin of 2,535.70% and a negative return on equity of 65.98%. As a group, sell-side analysts expect that CollPlant Biotechnologies will post -1.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in CollPlant Biotechnologies stock. Pinnacle Associates Ltd. boosted its holdings in shares of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) by 6.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 564,360 shares of the company’s stock after buying an additional 33,905 shares during the quarter. Pinnacle Associates Ltd. owned about 4.93% of CollPlant Biotechnologies worth $2,805,000 at the end of the most recent quarter. 21.69% of the stock is currently owned by institutional investors and hedge funds.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.